Josh TrentIdentity Transformation Architect and award winning Host of the Wellness + Wisdom Podcast—a decade-strong show with over 750 episodes and 15M downloads.

Ozempic vs Mounjaro 🔥 #ozempic #peptides #mounjaro #weightloss

29 May 2024 · 1 min

Watch on YouTube

0:57

A short conversational transcript excerpt comparing Ozempic (semaglutide) and tirzepatide (Mounjaro), focusing on differences in mechanisms, weight-loss effects, side-effect profiles, and suitability. The speaker explains that Ozempic was approved for type 2 diabetes (not originally for weight loss), semaglutide acts on a single receptor while tirzepatide targets two receptors, and that tirzepatide tends to produce faster weight loss with fewer side effects; the speaker favors episodic, short-term use to kick-start commitment to lifestyle changes.

Chapters

You know, Ozempic was never approved for weight loss, is approved for type 2 diabetics, but the pharmaceutical company got their hands on it and said, wow, when we're giving this to diabetics, we're seeing a lot of weight loss. Can you paint a picture of clarity between the difference of Ozempic and Tirzepatide and honestly, who they're even a fit for? The biggest difference is Manjiorno. Tirzepatide works on two different receptors, while semaglutide. Ozempic works on one. And what that translates to for two? Appetite. Manjiorno. You get faster weight loss with less side effects. And so who's this for? It's almost like everybody. What I like about it is that it's predictable and reliable and safe. The way I look at it, who doesn't want to look and feel their best? My philosophy is I'd like to help people win the race first and then when it clicks for them, they're going to be committed to figuring it out after that, and that's their buy in. My approach to it is I don't want it to be forever. I don't think really any pharmaceutical, I mean, very few are forever from go. And so we just start out with, hey, let's do this episodically.